Nasdaq

Foghorn Therapeutics Advances FHD-909 in Phase 1 Trial for SMARCA4 Mutated Cancers with Promising Preclinical Data for Combination Therapies

Foghorn Therapeutics Inc. announced advancements in their clinical and preclinical programs, focusing on FHD-909 (LY4050784), a selective SMARCA2 inhibitor currently in a Phase 1 trial targeting ...
Nasdaq

Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook

Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non-small ...